Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (171-180 of 257) with videos related to

Pageof 26
Sort By:
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
British Journal of Haematology|March 28, 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.
Blood|February 1, 2015
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceBenjamin Hebraud, Florence Magrangeas, Alice Cleynen, et al.
Leukemia & Lymphoma|October 3, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX studyNizar J Bahlis, Jeffrey Zonder, Lionel Karlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA TrialAurore Perrot, Thierry Facon, Torben Plesner, et al.
Pageof 26

Showing results (171-180 of 257) with videos related to

Sort By:
Pageof 26
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
British Journal of Haematology|March 28, 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myelomaLaurent Garderet, Frederique Kuhnowski, Benoit Berge, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trialSaad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, et al.
Nature Communications|January 13, 2021
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaEileen M Boyle, Shayu Deshpande, Ruslana Tytarenko, et al.
Blood|February 1, 2015
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experienceBenjamin Hebraud, Florence Magrangeas, Alice Cleynen, et al.
Leukemia & Lymphoma|October 3, 2025
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX studyNizar J Bahlis, Jeffrey Zonder, Lionel Karlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA TrialAurore Perrot, Thierry Facon, Torben Plesner, et al.
Pageof 26